Genzyme Launches Fifth Annual Patient Advocacy Leadership (PAL) Awards Program
July 29 2015 - 7:00AM
Business Wire
Awards will recognize collaborative and
innovative patient advocacy programs aimed at supporting the global
lysosomal storage disorder community
Genzyme, a Sanofi company, has launched the fifth annual Patient
Advocacy Leadership (PAL) Awards program for non-profit
organizations that serve the lysosomal storage disorder (LSD)
patient community. The PAL Awards program seeks to spark innovative
collaborations in disease awareness programs and patient support
initiatives around the world. Genzyme’s Patient Advocacy Leadership
Awards (PAL Awards) program is open to non-profit organizations
that serve the lysosomal storage disorder (LSD) patient community
and designed to support disease awareness programs and patient
support initiatives around the world.
Through this competitive program, funds are granted to
nonprofit, charitable patient organizations that seek funding for
new initiatives that support the LSD community. In its fifth year,
the program is evolving in 2015 to focus more on initiatives that
involve two or more organizations collaborating together to support
their broader LSD community, including regional and country
collaborations and across various disease communities. The goal is
to highlight and support programs that enable knowledge and best
practice sharing, and work to unite the broader LSD community. For
the first time this year, translation services will be provided to
patient organizations seeking to apply in languages other than
English. Submissions will be accepted now through September 30,
2015, when an External Review Committee will evaluate and select
recipients. A total of $50,000 will be awarded through this year’s
program.
“Patient organizations play a vital role in facilitating access
to care and provide support for patients and their families around
the world, and therefore supporting their work is critical to
optimizing patient care and increasing disease awareness,” said
Genzyme’s Head of Global Rare Diseases, Richard Peters, MD, Ph.D.
“From travelling photo exhibits and video projects, to digital
technology applications and mentoring programs, previous grant
recipients have demonstrated their creativity, intensity and
passion to improve the lives of patients living with LSDs through
their submissions. We look forward to supporting more of these
great efforts.”
Since 2011, more than $400,000 has been awarded to 37 patient
organizations around the world to support disease awareness,
community mobilization, non-profit development and good governance
activities. For more information on the Genzyme PAL Awards program,
or to apply for a grant, please visit
www.genzymeadvocacyawards.com.
About Lysosomal Storage DisordersLysosomal storage
disorders (LSDs) are a group of more than 40 diseases. Each is
caused by a genetic problem that results in the deficiency or
malfunction of particular enzymes needed to remove waste material
from cells. These waste molecules then accumulate, or are stored,
in cell lysosomes (smaller compartments within the cells),
disrupting cell function and causing a variety of symptoms. All
LSDs are progressive, meaning that without treatment, they worsen
over time. Each LSD is caused by a different genetic problem and
enzyme deficiency. Because these disorders are extremely rare –
even the most common, Gaucher disease, only affects an estimated
10,000 people worldwide – it can be difficult to find information
about them.
About Genzyme, a Sanofi CompanyGenzyme has pioneered the
development and delivery of transformative therapies for patients
affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the
compassion and commitment of our employees. With a focus on rare
diseases and multiple sclerosis, we are dedicated to making a
positive impact on the lives of the patients and families we serve.
That goal guides and inspires us every day. Genzyme’s portfolio of
transformative therapies, which are marketed in countries around
the world, represents groundbreaking and life-saving advances in
medicine. As a Sanofi company, Genzyme benefits from the reach and
resources of one of the world’s largest pharmaceutical companies,
with a shared commitment to improving the lives of patients. Learn
more at www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation. All
rights reserved.
About SanofiSanofi, a global and diversified healthcare
leader, discovers, develops and distributes therapeutic solutions
focused on patients’ needs. Sanofi has core strengths in the field
of healthcare with seven growth platforms: diabetes solutions,
human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
the Group's ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact
of cost containment policies and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2014. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150729005128/en/
GenzymeMedia Contact:Ingrid
Mitchell, 617-768-6699Ingrid.Mitchell@genzyme.com
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From May 2023 to May 2024